These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 28164753)
1. Evaluation of the Influence of the Conjugation Site of the Chelator Agent HYNIC to GLP1 Antagonist Radiotracer for Insulinoma Diagnosis. Faintuch BL; Seo D; de Oliveira EA; Targino RC; Moro AM Curr Radiopharm; 2017; 10(1):65-72. PubMed ID: 28164753 [TBL] [Abstract][Full Text] [Related]
2. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Gotthardt M; Fischer M; Naeher I; Holz JB; Jungclas H; Fritsch HW; Béhé M; Göke B; Joseph K; Behr TM Eur J Nucl Med Mol Imaging; 2002 May; 29(5):597-606. PubMed ID: 11976797 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of Re/ Radford LL; Papagiannopoulou D; Gallazzi F; Berendzen A; Watkinson L; Carmack T; Lewis MR; Jurisson SS; Hennkens HM Bioorg Med Chem; 2019 Feb; 27(3):492-501. PubMed ID: 30594453 [TBL] [Abstract][Full Text] [Related]
4. Development of Kimura H; Matsuda H; Ogawa Y; Fujimoto H; Toyoda K; Fujita N; Arimitsu K; Hamamatsu K; Yagi Y; Ono M; Inagaki N; Saji H Bioorg Med Chem; 2017 Feb; 25(4):1406-1412. PubMed ID: 28089587 [TBL] [Abstract][Full Text] [Related]
5. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. Wild D; Béhé M; Wicki A; Storch D; Waser B; Gotthardt M; Keil B; Christofori G; Reubi JC; Mäcke HR J Nucl Med; 2006 Dec; 47(12):2025-33. PubMed ID: 17138746 [TBL] [Abstract][Full Text] [Related]
6. [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Wicki A; Wild D; Storch D; Seemayer C; Gotthardt M; Behe M; Kneifel S; Mihatsch MJ; Reubi JC; Mäcke HR; Christofori G Clin Cancer Res; 2007 Jun; 13(12):3696-705. PubMed ID: 17575235 [TBL] [Abstract][Full Text] [Related]
7. Superior Diagnostic Performance of the GLP-1 Receptor Agonist [Lys Senica K; Tomazic A; Skvarca A; Kolenc Peitl P; Mikolajczak R; Hubalewska-Dydejczyk A; Lezaic L Mol Imaging Biol; 2020 Feb; 22(1):165-172. PubMed ID: 31098984 [TBL] [Abstract][Full Text] [Related]
8. 18F-radiolabeled GLP-1 analog exendin-4 for PET/CT imaging of insulinoma in small animals. Wu H; Liang S; Liu S; Pan Y; Cheng D; Zhang Y Nucl Med Commun; 2013 Jul; 34(7):701-8. PubMed ID: 23652208 [TBL] [Abstract][Full Text] [Related]
9. A freeze-dried kit formulation for the preparation of Lys(27)(99mTc-EDDA/HYNIC)-Exendin(9-39)/99mTc-EDDA/HYNIC-Tyr3-Octreotide to detect benign and malignant insulinomas. Medina-García V; Ocampo-García BE; Ferro-Flores G; Santos-Cuevas CL; Aranda-Lara L; García-Becerra R; Ordaz-Rosado D; Melendez-Alafort L Nucl Med Biol; 2015 Dec; 42(12):911-6. PubMed ID: 26364504 [TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma. Sowa-Staszczak A; Pach D; Mikołajczak R; Mäcke H; Jabrocka-Hybel A; Stefańska A; Tomaszuk M; Janota B; Gilis-Januszewska A; Małecki M; Kamiński G; Kowalska A; Kulig J; Matyja A; Osuch C; Hubalewska-Dydejczyk A Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):524-31. PubMed ID: 23224740 [TBL] [Abstract][Full Text] [Related]
11. Preliminary evaluation of [18F]AlF-NOTA-MAL-Cys39-exendin-4 in insulinoma with PET. Xu Q; Zhu C; Xu Y; Pan D; Liu P; Yang R; Wang L; Chen F; Sun X; Luo S; Yang M J Drug Target; 2015; 23(9):813-20. PubMed ID: 25758750 [TBL] [Abstract][Full Text] [Related]
12. Pancreas and liver uptake of new radiolabeled incretins (GLP-1 and Exendin-4) in models of diet-induced and diet-restricted obesity. Seo D; Faintuch BL; Aparecida de Oliveira E; Faintuch J Nucl Med Biol; 2017 Jun; 49():57-64. PubMed ID: 28365524 [TBL] [Abstract][Full Text] [Related]
13. 99mTc Labeled Glucagon-Like Peptide-1-Analogue (99mTc-GLP1) Scintigraphy in the Management of Patients with Occult Insulinoma. Sowa-Staszczak A; Trofimiuk-Müldner M; Stefańska A; Tomaszuk M; Buziak-Bereza M; Gilis-Januszewska A; Jabrocka-Hybel A; Głowa B; Małecki M; Bednarczuk T; Kamiński G; Kowalska A; Mikołajczak R; Janota B; Hubalewska-Dydejczyk A PLoS One; 2016; 11(8):e0160714. PubMed ID: 27526057 [TBL] [Abstract][Full Text] [Related]
14. Radiolabeled glucagon-like peptide-1 analogues: a new pancreatic β-cell imaging agent. Zhang Y; Chen W Nucl Med Commun; 2012 Mar; 33(3):223-7. PubMed ID: 22262216 [TBL] [Abstract][Full Text] [Related]
16. Pre-clinical evaluation of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 for imaging of insulinoma. Selvaraju RK; Velikyan I; Asplund V; Johansson L; Wu Z; Todorov I; Shively J; Kandeel F; Eriksson B; Korsgren O; Eriksson O Nucl Med Biol; 2014 Jul; 41(6):471-6. PubMed ID: 24857864 [TBL] [Abstract][Full Text] [Related]
17. Radioiodinated Exendin-4 Is Superior to the Radiometal-Labelled Glucagon-Like Peptide-1 Receptor Probes Overcoming Their High Kidney Uptake. Läppchen T; Tönnesmann R; Eersels J; Meyer PT; Maecke HR; Rylova SN PLoS One; 2017; 12(1):e0170435. PubMed ID: 28103285 [TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes. Ebinger M; Jehle DR; Fussgaenger RD; Fehmann HC; Jehle PM Am J Physiol Endocrinol Metab; 2000 Jul; 279(1):E88-94. PubMed ID: 10893327 [TBL] [Abstract][Full Text] [Related]
19. Development of 68Ga- and 89Zr-Labeled Exendin-4 as Potential Radiotracers for the Imaging of Insulinomas by PET. Bauman A; Valverde IE; Fischer CA; Vomstein S; Mindt TL J Nucl Med; 2015 Oct; 56(10):1569-74. PubMed ID: 26251418 [TBL] [Abstract][Full Text] [Related]
20. Radiolabeled new somatostatin analogs conjugated to DOMA chelator used as targeted tumor imaging agent: synthesis and radiobiological evaluation. De K; Banerjee I; Misra M Amino Acids; 2015 Jun; 47(6):1135-53. PubMed ID: 25743164 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]